JPRN-UMIN000009967尚未招募2 期
Prevention of recurrence undergoing additional intravesical therapy with pirarubicin for non-muscule invasive bladder cancer. - Prevention of recurrence undergoing additional intravesical therapy with pirarubicin for non-muscule invasive bladder cancer.
Department of Urology Kobe university graduate school of medicine0 个研究点目标入组 110 人开始时间: 2013年2月7日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Active multiple cancers (2) Patients with historically or presently disease of upper urinary tract urothelial cell carcinoma. (3) Target at BCG therapy (unrelated 2nd TUR) (4) Funcion of all organs are without severe dysfunction. (5) Lymph node metastasis or ogan metastasis (6) After TURBT,patients who didn`t undergo intravesical therapy with pirarubicin. (7) Patients who previously underwent intravesical therapy with BCG. (8) Inappropriate patients for this study judged by the physicians
研究者
相似试验
进行中（未招募）
1 期
Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment (PRESENT)EUCTR2011-005219-98-HUGalena Biopharma, Inc700
进行中（未招募）
1 期
Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment (PRESENT)Operable early-stage, node-positive breast cancerMedDRA version: 19.0Level: LLTClassification code 10071113Term: Node-positive breast cancerSystem Organ Class: 100000004864EUCTR2011-005219-98-BGGalena Biopharma, Inc709
进行中（未招募）
1 期
Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment (PRESENT)Operable early-stage, node-positive breast cancerMedDRA version: 18.1Level: LLTClassification code 10071113Term: Node-positive breast cancerSystem Organ Class: 100000004864EUCTR2011-005219-98-GBGalena Biopharma, Inc709
进行中（未招募）
1 期
Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment (PRESENT)EUCTR2011-005219-98-DEGalena Biopharma, Inc709
进行中（未招募）
1 期
Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax™ Treatment (PRESENT)Operable early-stage, node-positive breast cancerMedDRA version: 17.0Level: LLTClassification code 10071113Term: Node-positive breast cancerSystem Organ Class: 100000004864EUCTR2011-005219-98-CZGalena Biopharma, Inc709